Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 11 Show results per page	View Search Criteria \| Help With Results

Last Modified: 9/29/2008 First Published: 2/26/2008


1.		Phase I/II Study of Reduced-Intensity Preparative Regimen Comprising Fludarabine, Busulfan, and Alemtuzumab Followed By Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies or Other Diseases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				70 and under				Other				BCM-H-19386 BCM-FAB, H 19386, NCT00625144


2.		A Multi-Center Phase I Study of AP23573 in Pediatric Patients With Advanced Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				1 to 17				Other				SUN08-01 NCT00704054

Last Modified: 5/21/2008 First Published: 12/20/2007


3.		Phase II Study of Graft-Versus-Host Prophylaxis Comprising Sirolimus, Tacrolimus, and Anti-Thymocyte Globulin in Patients Undergoing Unrelated-Donor Hematopoietic Cell Transplantation For Hematological Malignancy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care, Treatment				Active				2 and over				NCI				CHNMC-06141 06141, NCT00589563

Last Modified: 10/14/2008 First Published: 7/24/2008


4.		Phase II Study of Unrelated Donor Umbilical Cord Blood Transplantation Using a Reduced-Intensity Preparative Regimen in Patients With Hematological Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				Any age				NCI				FHCRC-2239.00 FHCRC-2239.00, FHCRC-IR-6722, NCT00723099

Last Modified: 9/17/2008 First Published: 11/5/2007


5.		Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents, and Young Patients With Advanced or Refractory Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Treatment				Active				3 to 21				NCI				NCI-08-C-0007 08-C-0007, NCI-P6068, 7458, NCT00556881

Last Modified: 5/27/2008 First Published: 1/9/2008


6.		Phase I Study of Umbilical Cord Blood (UCB)-Derived CD25+CD4+ T-Regulatory Cell Infusion After Nonmyeloablative UCB Transplantation in Patients With Advanced Hematologic Cancer and Other Disorders

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				12 to 70				NCI				UMN-2007LS022 UMN-2007LS022, UMN-MT2006-01, UMN-0701M00303, UMN-12559, UMN-6220-04, NCT00602693


7.		Total Body Irradiation With Fludarabine Followed by Combined UCB Transplants

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				14 to 65				Other				7539 NCT00606437

First Published: 5/1/2008


8.		Phase I Study of Autologous or Allogeneic LMP-Specific Cytotoxic T-Lymphocytes in Patients With Epstein-Barr Virus (EBV)-Positive Lymphoma, Lymphoepithelioma, or Severe Chronic Active EBV Infection Syndrome

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				Any age				Other				BCM-H-9936-ALCI H 9936, NCT00671164


9.		Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and under				Other				NKHEM NCT00697671


10.		Doxil, Bevacizumab and Temsirolimus Trial

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Treatment				Active				12 and over				Other				2008-0384 NCT00761644

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute